Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Next Previous
Trial Profile

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan (Primary)
  • Indications Liver metastases; Uveal melanoma
  • Focus Adverse reactions; Expanded access
  • Sponsors Delcath Systems

Most Recent Events

  • 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.
  • 01 Sep 2023 According to Delcath Systems, Inc media release, company announced commercial product available for uveal melanoma patients by the end of 2023 and until that time patients will continue to be enrolled and treated at Expanded Access Program (EAP) sites.
  • 01 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top